Cazzaniga S, Anzengruber F, Augustin M, et al. - Researchers examined a large group of patients observed in real-life clinical practice to explore the main associations between patients’ characteristics and systemic treatments prescribed for psoriasis. From the Swiss Dermatology Network for Targeted Therapies registry in Switzerland, they included 549 patients (mean age 46.7 ± 14.7 years) in the analysis. The patients with no previous systemic therapies for psoriasis, with a moderate quality of life (QoL) at therapy onset and older age (≥ 60 years) were administered conventional therapies such as retinoids and methotrexate. Administration of fumaric acid derivatives was noted in correlation with mild psoriasis (psoriasis area severity index < 10) and long disease duration (≥ 20 years). On the other side, more severe condition, including impaired QoL, hospitalization and inability to work, were more frequently managed with cyclosporine and psoralen and ultraviolet A/ultraviolet B treatments. Use of biological therapies, both infliximab and adalimumab, was observed in correlation with the presence of psoriatic arthritis, severe disease condition and other comorbidities, including chronic liver or kidney diseases and tuberculosis. In cases with a complex history of previous systemic treatments for psoriasis, moderate disease condition, overweight and university education, use of etanercept, ustekinumab and secukinumab was observed. Findings thereby indicate multifaceted associations between patients’ characteristics, comorbidities, disease severity and systemic treatments prescribed for psoriasis. In particular, comorbidities are identified playing a central role in decision-making of systemic treatment usage for psoriasis.